---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-098078"
form_type: "8-K"
ticker: null
cik: "0001633932"
company_name: "ESSA Pharma Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:11:39.790711+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# ESSA Pharma acquired by XenoTherapeutics for $0.1242/share plus CVR; shares to be delisted

## Summary
- Shareholders received US$0.1242 per common share plus one CVR per share worth up to US$0.14.
- Aggregate potential CVR payment of US$6.7 million dependent on contingent liabilities.
- Final court order from Supreme Court of British Columbia obtained on October 7, 2025.
- All directors resigned; Jon Adkins (Xeno Acquisition Corp.) becomes sole director.
- ESSA requested Nasdaq delisting effective October 10, 2025; Form 15 to terminate registration.

## SEC filing metadata
- accession: 0001104659-25-098078
- form_type: 8-K
- cik: 0001633932
- company_name: ESSA Pharma Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1633932/000110465925098078/0001104659-25-098078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1633932/000110465925098078/tm2528270d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-098078
- JSON: https://secwatch.observer/filing/0001104659-25-098078.json
- Plain text: https://secwatch.observer/filing/0001104659-25-098078.txt

## Source-grounded claims
- claim_id: 4a48954ac9b2a87c443bb59515d470901bb3cd30
  claim: ESSA Pharma Inc. underwent a change of control involving XenoTherapeutics, Inc. for US$0.1242 per Share, plus one contingent value right per Share representing up to US$0.14 per CVR (closed 2025-10-09).
  evidence_excerpt: y and among the Company, XenoTherapeutics, Inc., a Massachusetts non-profit corporation (“Xeno”), Xeno Acquisition Corp.,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1633932/000110465925098078/0001104659-25-098078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.